Adding niraparib and dostarlimab to definitive CRT improved 1-year PFS in cisplatin-fit patients, although toxicity drove frequent discontinuations.

The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.

The top 5 OncLive TV videos of the week cover insights in endometrial cancer, mCRPC, germ cell tumors, melanoma, and HNSCC.

Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.

Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.

KEYNOTE-412 ctDNA data tie early clearance to longer survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.